Stay updated on Pembrolizumab in Untreated Extensive SCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Untreated Extensive SCLC Clinical Trial page.

Latest updates to the Pembrolizumab in Untreated Extensive SCLC Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe record now presents details of the completed pembrolizumab trial for extensive-stage small cell lung cancer, including its treatment arms, eligibility criteria, outcomes, and study locations.SummaryDifference54%

- Check19 days agoChange DetectedThe page no longer displays a 403 Forbidden message and instead shows the standard ClinicalTrials.gov interface, with the study content area appearing blank. The site revision label changes from v3.7.2 to v3.8.0.SummaryDifference0.6%

- Check26 days agoChange DetectedA sitewide NIH notice announces transition updates and says federal agencies are using “Super Intelligence” instead of “Artificial Intelligence.”SummaryDifference1%

- Check33 days agoChange DetectedThe footer revision label changes from v3.7.1 to v3.7.2 on the 403 Forbidden page.SummaryDifference0.2%

- Check40 days agoChange DetectedThe footer revision number changed from v3.7.0 to v3.7.1; the page remains a 403 Forbidden error.SummaryDifference0.2%

- Check61 days agoChange DetectedThe page now loads a 403 Forbidden error instead of the expected study details, indicating access to the record is blocked. The visible content shows a 403 message and header HTML, replacing the usual study information and navigation.SummaryDifference18%

Stay in the know with updates to Pembrolizumab in Untreated Extensive SCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Untreated Extensive SCLC Clinical Trial page.